Tetanus
medical conditions

Tetanus

Explore the available health information, treatment context, and integrative evidence for Tetanus.

Background
  • Tetanus, also called lockjaw, is a serious illness caused by tetanospasmin, a powerful nerve toxin produced by Clostridium tetani. The bacterium Clostridium tetani is an organism capable of living many years in the soil as a spore. Tetanus occurs when a wound becomes contaminated with bacterial spores. Infection follows when spores become active, multiply, and produce a very powerful poison that affects the muscles. Tetanus spores are found throughout the environment, usually in soil, dust, and animal waste (such as manure). Clostridium may enter the body through a deep cut, such as cuts acquired when stepping on a nail, from splinters, insect bites, burns, injection-drug sites, or puncturing the skin with a sharp object. Deep wounds or those with devitalized (dead) tissue are particularly prone to tetanus infection.
  • Tetanus is not transmitted from person to person. An individual usually becomes infected with tetanus when dirt enters a wound or cut.
  • The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw, which makes it impossible to open the mouth or swallow. If this occurs, the individual may suffocate. Due to symptoms, tetanus is frequently a fatal infectious disease.
  • If an individual gets tetanus, there is usually a long course of treatment. Drugs that increase immunity to fight infection, and decrease muscle spasms are used. Tetanus is curable, but depending on the severity and number of symptoms up to 50% of individuals with tetanus may die. The tetanus vaccine is effective, but its protection does not last forever. Adults should get a tetanus shot, or booster, every 10 years.
  • There are four types of tetanus: generalized, local, cephalic, and neonatal. In generalized tetanus, all skeletal muscles can be affected. Generalized tetanus is the most common, as well as the most severe form of tetanus. Death is usually due to respiratory failure or disturbance of heart rhythm. Local tetanus causes muscle spasms at or near the wound that has been infected with the bacteria. Cephalic tetanus primarily affects one or more muscles in the face. No muscles elsewhere are involved, unless the disease progresses to generalized tetanus. Neonatal tetanus is a common and serious tetanus infection found in newborn babies. Most infants who get the disease die. Neonatal tetanus is particularly common in rural areas where most deliveries are at home without adequate sterile procedures. In 2000, WHO estimates that neonatal tetanus killed about 200,000 infants.
  • Before World War II, when the vaccine came into widespread use, about 600 cases of tetanus and 180 deaths were reported annually in the United States. Now there are about 70 cases per year and 15 deaths, most of them in elderly adults. Overall, the mortality rate is approximately 45%.
  • Worldwide, tetanus is predominantly a disease of underdeveloped countries located in warm, damp climates. In developing countries of Africa, Asia, and South America, tetanus is far more common. The annual worldwide incidence is between 300,000-500,000 cases.
Risk Factors and Causes
  • The cause of tetanus is the bacterium Clostridium tetani. The bacteria are found in two forms: as a spore (dormant) or as a vegetative cell (active). The spores are in soil, dust, and animal waste and can survive there for many years. These spores are resistant to extremes of temperature. Contamination of a wound with bacteria such as C. tetani is rather common. Tetanus, however, can only occur when the spores germinate and turn into the active form. The active cells release three toxins, and one of these toxins, tetanospasmin, is responsible for the disease.
  • The disease typically follows an acute injury that results in a break in the skin. Most cases result from a puncture wound, laceration (cut), or an abrasion (scrape). Other tetanus-prone injuries include frostbite, surgery, crush wounds (occur when heavy objects fall on a person), abscesses (pocket of puss), childbirth, and intravenous (IV) drug use (at the site of needle injection). Stepping on a nail accounts for 32% of the puncture wounds.
  • Wounds with devitalized (dead) tissue or foreign bodies (debris) in them are at highest risk for developing tetanus. This occurs mostly in individuals suffering from burns and crush wounds.
  • Tetanus may develop in people who are not immunized against it or in people who have failed to maintain adequate immunity with active booster doses of the vaccine.
  • The tetanus toxin affects the site of interaction between the nerve and the muscle that it stimulates. This region is called the neuromuscular junction. The tetanus toxin heightens the chemical signal from the nerve to the muscle causing the muscles to experientially tighten via continuous ("tetanic" or "tonic") contractions or spasms. The result is either localized or generalized muscle spasms.
  • Tetanus toxin can affect infants causing muscle spasms, seizures, and the inability to nurse. This typically occurs within the first two weeks of birth and is associated with poor sanitation methods in caring for the umbilical cord stump.
  • Race: Since 1998, the incidence of tetanus in the United States was highest among Latinos (0.38 cases per million population), followed by Caucasians (0.13 cases per million population), and then African Americans (0.12 cases per million population).
  • Sex: A difference in the levels of tetanus immunity exists between the sexes. In the United States from 1998-2000, the incidence of tetanus in males aged 59 years and younger was 2.8 times higher than in females in the same age range. In developing countries, women have an increased immunity where tetanus toxoid is administered to women of childbearing age to prevent neonatal tetanus.
  • Age: The incidence of tetanus increases with advancing age. In U.S. patients, 36% are older than 59 years and only 9% are younger than 20 years.
Signs and Symptoms
  • The incubation period between contamination of a wound to the bacteria and development of the initial symptoms of tetanus ranges from two days to two months. The incubation period is the amount of time between infection with a virus or bacteria to the start of symptoms. Most commonly initial symptoms emerge within 14 days of injury. The shorter the incubation period of tetanus, the higher the risk of death.
  • During a one to seven day period, progressive muscle spasms caused by the tetanus toxin in the localized wound area may progress to involve the entire body. Restlessness, headache, sore muscles, weakness, and irritability are common. In children and adults, muscular stiffness in the jaw is a common first sign of tetanus.
  • In general, the tetanus neurotoxin causes the muscles to tighten up into a continuous ("tetanic" or "tonic") contraction or spasm. The jaw is "locked" by muscle spasms, giving the name "lockjaw" (also called "trismus"). Muscles throughout the body are affected, including the vital muscles necessary for normal breathing. When the breathing muscles lose their power, breathing becomes difficult or impossible and death can occur without life-support measures. Even with breathing support, infections of the airways within the lungs can lead to death.
  • In cephalic tetanus, in addition to having lockjaw, weakness of at least one other facial muscle occurs. In two-thirds of these cases, generalized tetanus will develop.
  • In localized tetanus, muscle spasms occur at or near the site of the injury. This condition rarely progresses to generalized tetanus.
  • Neonatal tetanus is identical to generalized tetanus except that it affects the newborn infant. Newborn babies with tetanus are normal at birth, but stop nursing between three and 28 days after birth.
Diagnosis
  • The diagnosis of generalized tetanus is made using a combination of the following: a history of incomplete tetanus immunizations; a recent injury resulting in skin breakage (not universal, only 70% of cases have an identified injury); progressive muscle spasms (starting in the facial region, especially lockjaw and progressing outward from the face to include all muscles of the body); fever; changes in blood pressure (especially high blood pressure); and irregular heartbeat. In localized tetanus, pain, cramps, or muscle spasms occur at or near a recent skin injury.
Complications
  • Fractures of the spine or other bones may occur as a result of muscle spasms and convulsions.
  • Arrhythmias (abnormal heartbeats) and coma can occur, as can development of pneumonia and other infections. In severe cases of tetanus, life-threatening respiratory and cardiovascular complications can present with troubling rapidity following the initial diagnosis and admission to the hospital. Individuals may have to be placed on a respirator to assist in breathing. Death is particularly likely in the very young and in the elderly.
Treatment
  • General measures to treat the sources of the bacterial infection with antibiotics, such as penicillin (PenG®), are used. Drainage of the wound site is also carried out in the hospital while the individual is monitored for any signs of compromised breathing muscles. Treatment is directed toward stopping toxin production, neutralizing its effects, and controlling muscle spasms. To treat tetanus, people are often paralyzed (to help stop the muscle spasms) using medications, such as vercuronium (Norcuron®) and then put on a mechanical ventilator to keep them breathing. Muscle relaxants and anti-seizure medicines are important.
  • Tetanus immune globulins (Hyper-Tet®, Bay-Tet®): Tetanus immune globulin (TIG, Hyper-Tet® or Bay-Tet®) is used as prophylaxis against tetanus and to treat patients with circulating tetanus toxin. TIG provides passive immunity. TIG should be used to treat all individuals with active tetanus, in combination with other supportive and therapeutic treatments such as antibiotics. TIG should also be used to prevent tetanus in individuals with inadequate or unknown immunization status after an acute injury.
  • Other drugs may be given for the following reasons: to provide sedation and control seizures, such as diazepam (Vaium®); relax the muscles, such as liorisal (Baclofen®); relieve pain, such as morphine (Astromorph®); and control heart arrhythmias and blood pressure, such as labetolol (Normodyne®).
  • For individuals with moderate to severe infections, a ventilator may be required to assist breathing. Because people with tetanus have trouble swallowing, nourishment is given intravenously or through a tube inserted through the nose and into the stomach.
  • Passive immunity: In individuals who exhibit the early symptoms of tetanus or in those whose immunization status is unknown or significantly out of date, the tetanus immune globulin (TIG) is injected into the muscle surrounding the wound with the remainder of the dose injected into the buttocks.
Prevention
  • Although many other diseases (for example, chickenpox) leave a person immune to further episodes of the disease, people who survive a tetanus infection are not immune to tetanus. Thus, the full series of vaccinations must be given after the person recovers. A full series of vaccinations includes the initial vaccination and boosters.
  • Vaccination: Tetanus toxoid (TT) vaccine protects against tetanus, but is rarely used now. TT vaccine protects only against tetanus and neonatal tetanus. Td, or tetanus-diphtheria toxoids adult dose vaccine, is the same vaccine as DT (diptheria/tetanus), but with a lower diphtheria toxoid dose. It is suitable for children older than six years old and adults, including pregnant women. Td has the added advantage of protecting against diphtheria and tetanus.
  • When given to women of childbearing age, vaccines that contain tetanus toxoid (TT or Td) not only protect women against tetanus, but also prevent neonatal tetanus in their newborn infants. When TT or Td vaccine is given to a woman who is or who becomes pregnant, the antibodies that form in her body are passed to her fetus. These antibodies protect the baby against tetanus during birth and for a few months afterwards. They also protect the woman against tetanus.
  • A three-dose course of TT or Td provides protection against maternal and neonatal tetanus for at least five years. A maximum of five doses will protect women throughout their childbearing years. Adults should continue to receive a booster dose of Td every 10 years.
  • Children: The best way to prevent tetanus is with the tetanus toxoid vaccine, which doctors often give in combination with vaccines against two other serious diseases, diphtheria and pertussis (whooping cough). This three-in-one combination is known as the DTaP vaccine. It is a newer and safer version of the DTP vaccine, which is no longer used in the United States. Doctors recommend beginning DTaP vaccination during infancy. The vaccine consists of a series of five shots typically administered in the arm and given to children at these ages: two months; four months; six months; 12-18 months; and four to six years. It takes at least three shots of the pertussis vaccine to fully protect a child against tetanus, but a total of five shots are recommended by age six.
  • Because immunity from the tetanus vaccine tends to wane by age 11, doctors recommend a booster shot for those in this age group (the tetanus, diphtheria and pertussis vaccine, or Tdap. DTaP is the name of the pediatric vaccine; Tdap is the name of the booster for people 11 years of age and older. The booster is given preferably at ages 11-12. This is in place of the traditional tetanus and diphtheria (Td) vaccine received at this age.
  • Adults: The U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices also advises adults to receive a Tdap booster shot every 10 years instead of the Td booster shot. The Tdap vaccine helps protect adults from tetanus. Adults who are or will be in close contact with infants under 12 months of age should also receive the vaccine. Side effects of the vaccine may include fever, crankiness, vomiting, or soreness at the site of the injection. These problems are more likely to occur after the fourth or fifth dose of the DTaP series than after earlier doses. After late doses, some children may develop injection site irritations such as swelling or localized redness of the arm or leg in which the shot was given. In rare cases, severe side effects may occur, including: serious allergic reactions, in which hives or a rash develop within minutes of the injection; high fever, greater than 105 degrees Fahrenheit; and seizures, shock, or coma. Immediate medical attention is necessary.
  • Some individuals are concerned that the vaccine may cause neurological (nerve) damage. Even though some children have developed brain damage after the immunizations, researchers have not found a definitive link between the vaccine and brain damage. Still, research into this issue is ongoing. Children with known seizure or brain disorders may not be candidates for the DTaP vaccine.
  • Other vaccines: In 2002, the U.S. Food and Drug Administration (FDA) approved a combination tetanus vaccine called Pediarix®. In addition to helping protect against tetanus, diphtheria and pertussis, Pediarix® immunizes children against polio and hepatitis B (a serious viral liver infection). Because Pediarix® protects against five diseases, children need fewer shots. However, the vaccine also causes a wider range of side effects than does DTaP. In studies, the most common side effects of Pediarix® were pain, redness, and swelling where the shot was given, fever, and fussiness. A pediatrician will help parents choose the best vaccination for their child.
References

Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.

  • American Academy of Pediatrics. . Accessed August 15, 2007.
  • Centers for Disease Control and Prevention. . Accessed August 15, 2007.
  • Mallick IH, Winslet MC. A review of the epidemiology, pathogenesis and management of tetanus. Int J Surg. 2004;2(2):109-12. View Abstract
  • Middleton DB, Zimmerman RK, Mitchell KB. Vaccine schedules and procedures, 2007. J Fam Pract. 2007;56(2 Suppl Vaccines):S47-60, C4-8. View Abstract
  • National Institute of Allergy and Infectious Diseases. . Accessed August 15, 2007.
  • Quinn HE, McIntyre PB. Tetanus in the elderly--An important preventable disease in Australia. Vaccine. 2007;25(7):1304-9. View Abstract
  • Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-43. View Abstract
  • World Health Organization. . Accessed August 15, 2007.
  • Zimmerman RK, Middleton DB, Burns IT, et al. Routine vaccines across the life span, 2007. J Fam Pract. 2007;56(2 Suppl Vaccines):S18-37, C1-3. View Abstract